{"schema_version":"secwatch.filing_event.v1","accession":"0001728117-25-000022","form_type":"8-K","ticker":"GOSS","cik":"0001728117","company_name":"Gossamer Bio, Inc.","filed_at":"2025-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.639627+00:00","generated_at":"2026-05-24T21:26:45.729472+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Gossamer Bio Q4 2024 net loss $33M; PROSERA Phase 3 topline due Q4 2025","bullets":["Cash, equivalents and marketable securities $294.5M at year-end; runway into H1 2027.","Full-year 2024 net loss $56.5M ($0.25/share) vs $179.8M ($1.18) in 2023.","R&D expenses $138.5M in 2024 vs $135.3M in 2023; G&A $36.1M vs $38.5M.","PROSERA Phase 3 in PAH on track for topline data readout in Q4 2025.","PH-ILD registrational Phase 3 to commence H2 2025; seralutinib got Japan orphan PAH designation."],"urls":{"canonical":"https://secwatch.observer/filing/0001728117-25-000022","json":"https://secwatch.observer/filing/0001728117-25-000022.json","markdown":"https://secwatch.observer/filing/0001728117-25-000022.md","text":"https://secwatch.observer/filing/0001728117-25-000022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728117/000172811725000022/0001728117-25-000022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728117/000172811725000022/goss-20250313.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T21:26:45.729472+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}